# Sovereign Data, Verified for Export

## Tier-2 Workloads and the Cross-Border Deals They Unlock

Prepared for M42 · Confidential · June 2026

M42's models are valuable, but its data, diagnostics, trials, and Med42 governance
assets are the larger prize — and each can be sold or licensed internationally
only when a foreign buyer, regulator, or partner can verify the result without
seeing the underlying records. That verification is the product. Each Tier-2
workload below produces a Digital Seal that supplies exactly the proof the
counterparty requires, turning a stalled conversation into a clearable deal.

| Workload | M42 asset | Cross-border deal it unlocks | What the Digital Seal proves to the counterparty |
|----------|-----------|------------------------------|--------------------------------------------------|
| De-identification & data-egress attestation | Malaffi, BioBank, genome data | De-identified data licensing to foreign pharma and research consortia; TELUS-style international data collaborations | PHI removed (recall >= 98%), zero residual PHI in the released set, k-anonymity >= 5 — before any record leaves the boundary |
| Malaffi population-health & RWE | ADHDS / Malaffi HIE — 3.5M records, 3,000+ facilities | Regulatory-grade real-world evidence sold to biopharma market-access teams; Malaffi/Sahatna HIE licensed to other governments | The cohort query ran on approved data, in-boundary, with a stated differential-privacy budget and 100% small-cell suppression — no record exposed |
| Biobank GWAS & polygenic risk scores | Emirati Genome Programme — 700K genomes | Biopharma target-discovery and PRS licensing on the sovereign cohort | Association power >= 80%, FDR <= 5%, genomic inflation controlled (lambda <= 1.10) — the cohort never left Abu Dhabi |
| Digital pathology AI | National Reference Laboratory | Cross-border diagnostic reads and second-opinion services | Slide AUROC >= 0.90, sensitivity >= 0.95, with the model and circuit hash bound to each slide read the receiving clinician can audit |
| Clinical-trial matching & synthetic control arms | IROS | Multi-site international trials and pharma trial partnerships | Eligibility matched at high sensitivity with a balanced synthetic control arm (covariate SMD <= 0.10) a regulator can accept in lieu of randomization |
| Med42 training / fine-tuning provenance | Med42 + Core42 / Cerebras | Licensing Med42 into other jurisdictions; defending its IP | Which approved, consented data trained the checkpoint — zero unapproved data included, complete lineage, bound to the checkpoint hash |

**The through-line.** De-identification attestation is the master key: no data
asset clears a foreign residency or consent review until M42 can prove safe
egress. The other five each convert a specific M42 asset into recurring,
cross-border revenue by replacing "trust M42's word" with "verify the Seal."

**Boundary.** Pilot evidence is synthetic and pre-testnet; the metrics above are
drill results computed on synthetic ground truth, not clinical, scientific, or
production claims. Live deals follow the paid pilot, ADGM entity registration,
and M42 governance approval.
